These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 23705689)

  • 21. Selective agonists and antagonists of formylpeptide receptors: duplex flow cytometry and mixture-based positional scanning libraries.
    Pinilla C; Edwards BS; Appel JR; Yates-Gibbins T; Giulianotti MA; Medina-Franco JL; Young SM; Santos RG; Sklar LA; Houghten RA
    Mol Pharmacol; 2013 Sep; 84(3):314-24. PubMed ID: 23788657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Matched molecular pair analysis in drug discovery.
    Dossetter AG; Griffen EJ; Leach AG
    Drug Discov Today; 2013 Aug; 18(15-16):724-31. PubMed ID: 23557664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity cliffs: facts or artifacts?
    Medina-Franco JL
    Chem Biol Drug Des; 2013 May; 81(5):553-6. PubMed ID: 23375049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Shifting from the single to the multitarget paradigm in drug discovery.
    Medina-Franco JL; Giulianotti MA; Welmaker GS; Houghten RA
    Drug Discov Today; 2013 May; 18(9-10):495-501. PubMed ID: 23340113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Scanning structure-activity relationships with structure-activity similarity and related maps: from consensus activity cliffs to selectivity switches.
    Medina-Franco JL
    J Chem Inf Model; 2012 Oct; 52(10):2485-93. PubMed ID: 22989212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early phase drug discovery: cheminformatics and computational techniques in identifying lead series.
    Duffy BC; Zhu L; Decornez H; Kitchen DB
    Bioorg Med Chem; 2012 Sep; 20(18):5324-42. PubMed ID: 22938785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CASE plots for the chemotype-based activity and selectivity analysis: a CASE study of cyclooxygenase inhibitors.
    Pérez-Villanueva J; Medina-Franco JL; Méndez-Lucio O; Yoo J; Soria-Arteche O; Izquierdo T; Lozada MC; Castillo R
    Chem Biol Drug Des; 2012 Nov; 80(5):752-62. PubMed ID: 22883137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How similar are those molecules after all? Use two descriptors and you will have three different answers.
    Bender A
    Expert Opin Drug Discov; 2010 Dec; 5(12):1141-51. PubMed ID: 22822717
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SAR matrices: automated extraction of information-rich SAR tables from large compound data sets.
    Wassermann AM; Haebel P; Weskamp N; Bajorath J
    J Chem Inf Model; 2012 Jul; 52(7):1769-76. PubMed ID: 22657271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activity landscape modeling of PPAR ligands with dual-activity difference maps.
    Méndez-Lucio O; Pérez-Villanueva J; Castillo R; Medina-Franco JL
    Bioorg Med Chem; 2012 Jun; 20(11):3523-32. PubMed ID: 22564380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expanding the medicinally relevant chemical space with compound libraries.
    López-Vallejo F; Giulianotti MA; Houghten RA; Medina-Franco JL
    Drug Discov Today; 2012 Jul; 17(13-14):718-26. PubMed ID: 22515962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MMP-Cliffs: systematic identification of activity cliffs on the basis of matched molecular pairs.
    Hu X; Hu Y; Vogt M; Stumpfe D; Bajorath J
    J Chem Inf Model; 2012 May; 52(5):1138-45. PubMed ID: 22489665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modeling of activity landscapes for drug discovery.
    Bajorath J
    Expert Opin Drug Discov; 2012 Jun; 7(6):463-73. PubMed ID: 22475223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploring activity cliffs in medicinal chemistry.
    Stumpfe D; Bajorath J
    J Med Chem; 2012 Apr; 55(7):2932-42. PubMed ID: 22236250
    [No Abstract]   [Full Text] [Related]  

  • 35. Multitarget structure-activity relationships characterized by activity-difference maps and consensus similarity measure.
    Medina-Franco JL; Yongye AB; Pérez-Villanueva J; Houghten RA; Martínez-Mayorga K
    J Chem Inf Model; 2011 Sep; 51(9):2427-39. PubMed ID: 21842860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Consensus models of activity landscapes with multiple chemical, conformer, and property representations.
    Yongye AB; Byler K; Santos R; Martínez-Mayorga K; Maggiora GM; Medina-Franco JL
    J Chem Inf Model; 2011 Jun; 51(6):1259-70. PubMed ID: 21609014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single R-Group Polymorphisms (SRPs) and R-cliffs: an intuitive framework for analyzing and visualizing activity cliffs in a single analog series.
    Agrafiotis DK; Wiener JJ; Skalkin A; Kolpak J
    J Chem Inf Model; 2011 May; 51(5):1122-31. PubMed ID: 21504183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Towards a systematic characterization of the antiprotozoal activity landscape of benzimidazole derivatives.
    Pérez-Villanueva J; Santos R; Hernández-Campos A; Giulianotti MA; Castillo R; Medina-Franco JL
    Bioorg Med Chem; 2010 Nov; 18(21):7380-91. PubMed ID: 20888242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Large-scale systematic analysis of 2D fingerprint methods and parameters to improve virtual screening enrichments.
    Sastry M; Lowrie JF; Dixon SL; Sherman W
    J Chem Inf Model; 2010 May; 50(5):771-84. PubMed ID: 20450209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extended-connectivity fingerprints.
    Rogers D; Hahn M
    J Chem Inf Model; 2010 May; 50(5):742-54. PubMed ID: 20426451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.